ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Locana raises $55 million for RNA editing

by Ryan Cross
May 31, 2019 | APPEARED IN VOLUME 97, ISSUE 22

Locana, a start-up that is developing CRISPR-based therapies that target and edit RNA, has raised $55 million in series A financing. The company was cofounded by University of California, San Diego, scientist Gene Yeo in 2016 after his lab reprogrammed CRISPR-Cas9 to cut RNA instead of DNA. That strategy could be used to destroy disease-causing RNA transcripts in conditions like amyotrophic lateral sclerosis and Huntington’s disease. Yeo says Locana is now looking beyond CRISPR for RNA-binding proteins that could be engineered for making RNA-editing therapies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment